The biotech sector has embraced the microbiome in recent years, a green field market powered by cheap genome sequencing and venture dollars, promising bespoke treatments for everything from gut troubles to skin problems. But a report in Science alleges that these companies lack scientific rigor and meaningful regulation, offering little more than guesswork on a […]
© 2024 TechCrunch. All rights reserved. For personal use only....